The estimated Net Worth of William J Federici is at least $2.33 Million dollars as of 13 June 2023. Mr. Federici owns over 115 units of Zynerba Pharmaceuticals Inc stock worth over $98,511 and over the last 19 years he sold ZYNE stock worth over $2,232,951. In addition, he makes $0 as Independent Director at Zynerba Pharmaceuticals Inc.
William has made over 11 trades of the Zynerba Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 115 units of ZYNE stock worth $40 on 13 June 2023.
The largest trade he's ever made was exercising 75,662 units of Zynerba Pharmaceuticals Inc stock on 8 June 2018 worth over $1,614,627. On average, William trades about 3,695 units every 40 days since 2005. As of 13 June 2023 he still owns at least 75,778 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Mr. Federici stock trades at the bottom of the page.
William J. Federici CPA serves as Independent Director of the Company. Mr. Federici served as senior vice president and chief financial officer of West Pharmaceutical Services, Inc., a publicly traded global pharmaceutical technology company, from August 2003 until June 2018. He served as a member of the board of directors and chairman of the Audit committee at NuPathe from January 2011 until February 2014. From June 2002 until August 2003, he was national industry director for Pharmaceuticals of KPMG LLP, and prior thereto, he was an audit partner with Arthur Andersen, LLP. Mr. Federici holds a B.A. in Economics and an M.B.A. in Professional Accounting from Rutgers University and is a Certified Public Accountant. With his leadership experience in the global pharmaceutical and accounting industries, Mr. Federici brings valuable expertise in financial and audit-related matters to our Board.
William Federici is 60, he's been the Independent Director of Zynerba Pharmaceuticals Inc since 2015. There are 9 older and 5 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
William's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVE., SUITE 300, DEVON, PA, 19333.
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici, and Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include: